DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Completed

Conditions: Recurrent Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma
Stage IV Prostate Cancer
Castration Levels of Testosterone
PSA Progression

Interventions: Other: Cytology Specimen Collection Procedure
Drug: Enzalutamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-08-29

Last Posted Date: 2020-09-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 41

Registration Number: NCT02228265

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Adenocarcinoma AJCC v7
Castration-Resistant Prostate Carcinoma
Metastatic Malignant Neoplasm in the Soft Tissues
Metastatic Prostate Adenocarcinoma
Metastatic Malignant Neoplasm in the Bone
Recurrent Prostate Carcinoma
Stage III Prostate Adenocarcinoma AJCC v7

Interventions: Drug: Enzalutamide

First Posted Date: 2014-03-31

Last Posted Date: 2024-03-22

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 36

Registration Number: NCT02099864

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Esophageal Cytology With FISH in Detecting Esophageal Cancer

Not Applicable

Completed

Conditions: Dysphagia
Weight Loss
Esophagitis
Esophageal Adenocarcinoma
Dysplasia
Esophageal Squamous Cell Carcinoma
Gastroesophageal Reflux Disease
High Grade Dysplasia in Barrett Esophagus

Interventions: Other: Cytology Specimen Collection Procedure
Procedure: Esophagogastroduodenoscopy
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-03-31

Last Posted Date: 2017-05-11

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 50

Registration Number: NCT02100189

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Neutrophilic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Ruxolitinib Phosphate

First Posted Date: 2014-03-20

Last Posted Date: 2020-11-16

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 51

Registration Number: NCT02092324

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

DCE MRI in Patients With Pancreatic Cancer

Not Applicable

Terminated

Conditions: Familial Pancreatic Cancer
Pancreatic Adenocarcinoma
Pancreatic Intraductal Papillary-Mucinous Neoplasm

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol

First Posted Date: 2014-02-25

Last Posted Date: 2025-01-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 77

Registration Number: NCT02070705

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Pleomorphic Rhabdomyosarcoma
Stage III Adult Soft Tissue Sarcoma AJCC v7
Stage IIB Adult Soft Tissue Sarcoma AJCC v7
Stage IV Adult Soft Tissue Sarcoma AJCC v7

Interventions: Drug: Epirubicin Hydrochloride
Radiation: External Beam Radiation Therapy
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2014-01-31

Last Posted Date: 2022-03-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02050919

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Blood Vessel Patterns in Small Choroidal Tumors

Active, not recruiting

Conditions: Small Posterior Choroidal Tumors

First Posted Date: 2013-10-08

Last Posted Date: 2022-10-12

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01955915

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Vascular Response to Brachytherapy Using Functional OCT

Completed

Conditions: Uveal Melanoma

First Posted Date: 2013-10-08

Last Posted Date: 2023-06-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 49

Registration Number: NCT01955941

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Recurrent Prostate Cancer
Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: abiraterone acetate
Dietary Supplement: dietary intervention
Other: pharmacological study
Other: questionnaire administration
Other: laboratory biomarker analysis

First Posted Date: 2013-07-31

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01913015

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Abraxane/Bevacizumab

Phase 2

Terminated

Conditions: Ovarian Cancer
Peritoneal Cancer

Interventions: Drug: Abraxane
Drug: Bevacizumab

First Posted Date: 2013-04-01

Last Posted Date: 2013-07-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01821859

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy